ECOR · electroCore, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Notwithstanding the expected cash flow from operations and expected access to capital from existing and/or future debt and equity sources, the Company's currently forecasted cash is less than the requirements to fund its operating expenses, future investments and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $36.97M | $32.03M | $25.18M | $16.03M | $8.59M | $5.45M | $3.5M | $2.39M | $992.95K | $811.46K | |
| $4.79M | $4.24M | $3.79M | $2.8M | $1.62M | $1.39M | $1.74M | $1.16M | $578.74K | $518.53K | |
| $32.18M | $27.79M | $21.4M | $13.23M | $6.98M | $4.07M | $1.76M | $1.23M | $414.21K | $292.93K | |
| — | 86.75% | 84.97% | 82.51% | 81.19% | 74.59% | 50.3% | 51.6% | 41.71% | 36.1% | |
| $3.14M | $2.74M | $2.36M | $5.32M | $5.52M | $2.54M | $4.2M | $9.9M | $12.47M | $7.83M | |
| $42.95M | $38.21M | $31.2M | $27.17M | $24.33M | $21.57M | $21.84M | $35.42M | $42.5M | $18.11M | |
| $252K | $501K | $760K | $962K | $548K | $382K | $399.24K | $249.58K | $66.66K | $32.31K | |
| — | — | — | — | — | — | $464.61K | — | — | — | |
| $46.09M | $40.94M | $33.56M | $32.5M | $29.85M | $24.11M | $26.51M | $47.32M | $54.97M | $25.94M | |
| -$13.91M | -$13.15M | -$12.16M | -$19.27M | -$22.87M | -$20.04M | -$24.75M | -$46.09M | -$54.55M | -$25.64M | |
| — | -41.06% | -48.3% | -120.21% | -266.22% | -367.69% | -707.94% | -1928.17% | -5494.07% | -3160.31% | |
| -$13.66M | -$12.65M | -$11.4M | -$18.31M | -$22.33M | -$19.66M | -$24.35M | -$45.84M | -$54.49M | -$25.61M | |
| $12.7K | $14.9K | $18.4K | — | $4000 | — | — | — | — | $6.3M | |
| -$1.13M | -$810K | $183K | $249K | $281K | $1.97M | $66.57K | $958.34K | -$1.21M | -$10.38M | |
| -$15.04M | -$13.96M | -$11.98M | -$19.02M | -$22.59M | -$18.07M | -$24.68M | -$45.13M | -$55.76M | -$36.03M | |
| -$270K | $3000 | -$93K | -$186K | -$431K | -$851K | -$1.17M | $17.7K | $2431 | — | |
| -$14.77M | -$13.97M | -$11.89M | -$18.83M | -$22.16M | -$17.22M | -$23.51M | -$45.15M | -$55.82M | -$35.79M | |
| — | -43.6% | -47.2% | -117.49% | -257.94% | -315.87% | -672.55% | -1888.81% | -5621.66% | -4410.88% | |
| — | — | — | — | — | — | — | — | $55.01K | -$236.36K | |
| — | — | — | -$18.83M | -$22.16M | -$17.22M | — | — | — | — | |
| -$14.73M | -$13.98M | -$11.71M | -$18.83M | -$22.24M | -$16.95M | -$23.72M | -$45.25M | -$55.79M | -$35.94M | |
| USD/shares | -$1.66 | -$1.65 | -$1.59 | -$3.42 | -$4.69 | -$4.36 | — | — | — | — |
| USD/shares | -$1.66 | -$1.65 | -$1.59 | -$3.42 | -$4.69 | -$4.36 | — | — | — | — |
| shares | — | 8483 | 7483 | 5.52M | 4729 | 3945 | 2.6M | 1.96M | 1.95M | — |
| shares | — | 8483 | 7483 | 5.52M | 4729 | 3945 | 2.6M | 1.96M | 1.95M | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 74 similar-size Medical Devices companies (of 150 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Bioelectronic Innovations Segment | $32,032,000 | $25,182,000 | — |
| Medical Devices Segment | — | — | $16,030,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $30,075,000 | $23,332,000 | $14,209,000 | $6,974,000 | $3,940,000 | $2,374,687 | $1,605,814 |
| United Kingdom | $1,695,000 | $1,666,000 | $1,571,000 | $1,296,000 | $1,344,000 | $1,051,206 | $665,627 |
| Other Countries | $197,000 | $119,000 | $148,000 | $183,000 | — | — | — |
| Japan | $65,000 | $65,000 | $102,000 | $139,000 | — | — | — |
| Germany | — | — | — | — | — | $53,925 | $102,427 |
| Other | — | — | — | — | $167,000 | $16,014 | $16,411 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Product | $31,967,000 | $25,117,000 |
| License | $65,000 | $65,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Bioelectronic Innovations Segment | -$13,153,000 | -$12,162,000 | — |
| Medical Devices Segment | — | — | -$19,269,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Bioelectronic Innovations Segment | -41.1% | -48.3% | — |
| Medical Devices Segment | — | — | -120.2% |